Catalyst Pharmaceuticals to Participate in the 28th Annual Piper Jaffray Healthcare Conference
November 21 2016 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating diseases, today
announced that Patrick J. McEnany, Chief Executive Officer, and
Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific
Officer, will participate as part of the Underdiscovered
Neuro-Innovators Panel at the 28th Annual Piper Jaffray Healthcare
Conference being held at Lotte New York Palace, NY, November
29-30. The panel will take place Tuesday, November 29 at 10
am EST.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating diseases,
including Lambert-Eaton myasthenic syndrome (LEMS), congenital
myasthenic syndromes (CMS), infantile spasms, and Tourette's
Disorder. Firdapse® for the treatment of LEMS has received
Breakthrough Therapy Designation from the U.S. Food and Drug
Administration (FDA) and orphan drug designation for LEMS, CMS and
myasthenia gravis. Firdapse is the first and only approved drug
in Europe for symptomatic treatment in adults with
LEMS.
Catalyst is also developing CPP-115 to treat
infantile spasms, epilepsy and other neurological conditions
associated with reduced GABAergic signaling, like post-traumatic
stress disorder and Tourette's Disorder. CPP-115 has been
granted U.S. orphan drug designation for the treatment of
infantile spasms by the FDA and has been granted E.U.
orphan medicinal product designation for the treatment of West
Syndrome by the European Commission. In addition,
Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including whether the receipt of
breakthrough therapy designation for Firdapse will
expedite the development and review of Firdapse by
the FDA or the likelihood that the product will be found
to be safe and effective, the timing on Catalyst’s second trial
evaluating Firdapse for the treatment of LEMS and whether the trial
will be successful, whether Catalyst’s assumptions in its updated
business plan will be accurate and the impact of unanticipated
events or delays in projected activities on Catalyst’s cash
requirements and on Catalyst’s ability to get to an accepted NDA
submission for Firdapse without the need for additional funding,
what clinical trials and studies will be required before Catalyst
can resubmit an NDA for Firdapse for the treatment of CMS and
whether any such required clinical trials and studies will be
successful, whether the investigator-sponsored study evaluating
Firdapse for the treatment of MuSK-MG will be successful, whether
any NDA for Firdapse resubmitted to the FDA will ever be accepted
for filing, the timing of any such NDA filing or acceptance,
whether, if an NDA for Firdapse is accepted for filing, such NDA
will be given a priority review by the FDA, whether Firdapse
will ever be approved for commercialization, whether Catalyst will
be the first company to receive approval for amifampridine
(3,4-DAP), giving it 7-year marketing exclusivity for its product,
whether CPP-115 will be determined to be safe for humans, what
additional testing will be required before CPP-115 is “Phase 2
ready”, whether CPP-115 will be determined to be effective for the
treatment of infantile spasms, post-traumatic stress disorder,
Tourette's Disorder or any other indications, whether Catalyst can
successfully design and complete a bioequivalence study of its
version of vigabatrin compared to Sabril that is acceptable to
the FDA, whether any such bioequivalence study the design of
which is acceptable to the FDA will be successful,
whether any ANDA that Catalyst submits for a generic version of
Sabril will be accepted for filing, whether any ANDA for Sabril
accepted for filing by the FDA will be approved (and the
timing of any such approval), whether any of Catalyst's product
candidates will ever be approved for commercialization or
successfully commercialized, and those other factors described in
Catalyst's Annual Report on Form 10-K for the fiscal year 2015 and
its other filings with the U.S. Securities and Exchange
Commission (SEC), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 529-2522
pmcenany@catalystpharma.com
Media Contacts
David Schull
Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From May 2023 to May 2024